Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety, tolerability, pharmacokinetics,
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and ...
U.S. stock futures are pointing lower after major indexes neared or set all-time highs yesterday on encouraging earnings ...
Hosted on MSN10h
Novo Nordisk Stock Eyes Best Day In 17 Months On New Obesity Drug Trial Data: Retail Breathes EasyShares of Novo Nordisk surged over 13% in premarket trading Friday, driven by promising topline results from a early-stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback